XERS
NASDAQ HealthcareXeris Biopharma Holdings, Inc. - Common Stock
Biotechnology
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
�� 市场数据
| 价格 | $6.37 |
|---|---|
| 成交量 | 1,242,658 |
| 市值 | 1.10B |
| 贝塔系数 | 0.990 |
| RSI（14日） | 76.8 超买 |
| 200日均线 | $7.01 |
| 50日均线 | $6.11 |
| 52周最高 | $10.08 |
| 52周最低 | $3.95 |
| Forward P/E | 17.19 |
| Price / Book | 77.68 |
🎯 投资策略评分
XERS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (64/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (28/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 XERS in your text
粘贴任何文章、记录或帖子 — 工具将提取 XERS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.